American International Group Inc. lifted its stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 24.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,041 shares of the biopharmaceutical company’s stock after purchasing an additional 10,773 shares during the period. American International Group Inc. owned about 0.07% of Sangamo Therapeutics worth $826,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in the stock. EAM Investors LLC boosted its holdings in Sangamo Therapeutics by 91.1% in the third quarter. EAM Investors LLC now owns 213,027 shares of the biopharmaceutical company’s stock valued at $3,195,000 after purchasing an additional 101,541 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Sangamo Therapeutics in the third quarter valued at $953,000. Quantbot Technologies LP purchased a new position in Sangamo Therapeutics in the third quarter valued at $118,000. Russell Investments Group Ltd. boosted its holdings in Sangamo Therapeutics by 206.0% in the third quarter. Russell Investments Group Ltd. now owns 70,674 shares of the biopharmaceutical company’s stock valued at $1,060,000 after purchasing an additional 47,579 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Sangamo Therapeutics by 10.1% in the third quarter. Bank of New York Mellon Corp now owns 374,309 shares of the biopharmaceutical company’s stock valued at $5,614,000 after purchasing an additional 34,467 shares during the period. Hedge funds and other institutional investors own 64.33% of the company’s stock.
Sangamo Therapeutics Inc (NASDAQ SGMO) traded up $1.15 during trading on Friday, reaching $18.30. The company’s stock had a trading volume of 2,270,579 shares, compared to its average volume of 1,430,000. Sangamo Therapeutics Inc has a one year low of $3.35 and a one year high of $18.69. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. The firm has a market capitalization of $1,550.00, a PE ratio of -26.52 and a beta of 3.15.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company had revenue of $11.81 million for the quarter, compared to analysts’ expectations of $10.37 million. During the same period last year, the firm earned ($0.27) earnings per share. Sangamo Therapeutics’s quarterly revenue was up 333.0% on a year-over-year basis. analysts anticipate that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current year.
In other news, VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $17.11, for a total transaction of $85,550.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $17.26, for a total value of $258,900.00. Following the sale, the vice president now owns 13,015 shares in the company, valued at approximately $224,638.90. The disclosure for this sale can be found here. Insiders have sold 58,433 shares of company stock worth $979,696 in the last quarter. Insiders own 5.50% of the company’s stock.
A number of research firms recently issued reports on SGMO. BidaskClub lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Piper Jaffray Companies set a $25.00 price target on Sangamo Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Jefferies Group restated a “buy” rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Finally, Wedbush restated a “hold” rating and issued a $6.00 price target on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $18.83.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.